Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
The Cleveland Clinic Identifier:
First received: November 16, 2006
Last updated: May 13, 2011
Last verified: May 2007

RATIONALE: Drugs used in chemotherapy, such as gemcitabine and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

PURPOSE: This phase II trial is studying the side effects and how well giving gemcitabine together with irinotecan works in treating patients with metastatic kidney cancer.

Condition Intervention Phase
Kidney Cancer
Drug: gemcitabine hydrochloride
Drug: irinotecan hydrochloride
Phase 2

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of Gemcitabine Plus Irinotecan in Patients With Metastatic Renal Cell Carcinoma

Resource links provided by NLM:

Further study details as provided by The Cleveland Clinic:

Primary Outcome Measures:
  • Overall response [ Designated as safety issue: No ]
  • Safety and efficacy [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Difference in response to therapy in patients with clear vs nonclear cell renal cell carcinoma [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: May 2004
Detailed Description:


  • Determine the response rate in patients with epithelial (clear or nonclear cell) renal cell carcinoma (RCC) treated with gemcitabine hydrochloride and irinotecan hydrochloride.
  • Compare the response in patients with clear cell RCC vs nonclear cell RCC treated with this regimen.
  • Determine the toxicities of this regimen.

OUTLINE: This is an open-label study.

Patients receive gemcitabine hydrochloride IV over 30 minutes and irinotecan hydrochloride IV over 90 minutes on days 1 and 8. Treatment repeats every 21 days for at least 6 courses in the absence of unacceptable toxicity or disease progression.

After completion of study treatment, patients are followed every 3 months for 1 year.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed epithelial renal cell carcinoma (RCC), including either clear cell or nonclear cell RCC
  • Strong clinical evidence or biopsy proof of metastases to a site or sites distant from the primary tumor
  • Measurable disease
  • No untreated or progressive CNS metastases


  • ECOG performance status 0-1
  • Life expectancy > 3 months
  • Absolute neutrophil count > 1,500/mm³
  • Platelet count > 100,000/mm³
  • Hemoglobin > 9.5 g/dL
  • Creatinine ≤ 1.8 mg/dL
  • Bilirubin < 1.5 mg/dL
  • Calcium < 11.5 mg/dL
  • ALT and AST < 3 times upper limit of normal
  • No history of any of the following:

    • Serious cardiac arrhythmia or cardiac arrhythmia requiring treatment
    • Congestive heart failure
    • Angina pectoris
    • Other severe cardiovascular disease producing limitations of physical activity (i.e., New York Heart Association class III-IV heart disease)
  • No other prior malignancy except for the following:

    • Basal cell or squamous cell carcinoma of the skin
    • Carcinoma in situ of the uterine cervix
    • Any malignancy treated with curative intent and in complete remission for > 3 years
  • No active peptic ulcer disease, inflammatory bowel disease, or chronic diarrhea
  • No local or systemic infections requiring IV antibiotics within the past 28 days
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception


  • Recovered from prior hormonal therapy, radiotherapy, biologic therapy, or chemotherapy
  • No more than 3 prior therapeutic regimens for metastatic disease
  • No prior organ allograft
  • More than 28 days since prior major surgery requiring general anesthesia
  • More than 28 days since prior radiotherapy to control pain from skeletal lesions
  • More than 28 days since prior hormonal treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00401128

United States, Ohio
Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44106-5065
Sponsors and Collaborators
The Cleveland Clinic
National Cancer Institute (NCI)
Study Chair: Ronald M. Bukowski, MD The Cleveland Clinic
  More Information Identifier: NCT00401128     History of Changes
Other Study ID Numbers: CASE-CCF-6695  P30CA043703 
Study First Received: November 16, 2006
Last Updated: May 13, 2011
Health Authority: United States: Federal Government

Keywords provided by The Cleveland Clinic:
clear cell renal cell carcinoma
recurrent renal cell cancer
papillary renal cell carcinoma
stage IV renal cell cancer

Additional relevant MeSH terms:
Carcinoma, Renal Cell
Kidney Neoplasms
Kidney Diseases
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Anti-Infective Agents
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Topoisomerase I Inhibitors
Topoisomerase Inhibitors processed this record on April 27, 2016